Sunny Pharmtech (ROCO:6676) Debt-to-Equity : 0.34 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Sunny Pharmtech Debt-to-Equity?

Sunny Pharmtech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$43.6 Mil. Sunny Pharmtech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$352.1 Mil. Sunny Pharmtech's Total Stockholders Equity for the quarter that ended in Jun. 2024 was NT$1,162.3 Mil. Sunny Pharmtech's debt to equity for the quarter that ended in Jun. 2024 was 0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sunny Pharmtech's Debt-to-Equity or its related term are showing as below:

ROCO:6676' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.31 Med: 0.35 Max: 0.65
Current: 0.34

During the past 6 years, the highest Debt-to-Equity Ratio of Sunny Pharmtech was 0.65. The lowest was 0.31. And the median was 0.35.

ROCO:6676's Debt-to-Equity is ranked worse than
66.93% of 1025 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6676: 0.34

Sunny Pharmtech Debt-to-Equity Historical Data

The historical data trend for Sunny Pharmtech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunny Pharmtech Debt-to-Equity Chart

Sunny Pharmtech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.34

0.37

0.33

0.58

0.33

Sunny Pharmtech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial						0.44	0.58	0.65	0.33	0.34

Competitive Comparison of Sunny Pharmtech's Debt-to-Equity

For the Biotechnology subindustry, Sunny Pharmtech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunny Pharmtech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunny Pharmtech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sunny Pharmtech's Debt-to-Equity falls into.

Sunny Pharmtech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sunny Pharmtech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.131	+	376.296)	/	1199.926
	=	0.33

Sunny Pharmtech's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(43.649	+	352.058)	/	1162.285
	=	0.34

Sunny Pharmtech (ROCO:6676) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sunny Pharmtech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sunny Pharmtech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunny Pharmtech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunny Pharmtech Inc (ROCO:6676) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.255,Longyuan 1st Road, Hsinchu Science Park, Longtan District, Taoyuan, TWN, 325002

Website

http://www.sunnypharmtech.com

Sunny Pharmtech Inc is a specialty pharmaceutical company. It is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products, which includes orals, liquids, semi-solids, and parenterals.

Sunny Pharmtech Headlines

No Headlines